• Fulfilling the promise of cell & gene therapies through manufacturing (Part I)

  • May 10 2024
  • Length: 29 mins
  • Podcast
Fulfilling the promise of cell & gene therapies through manufacturing (Part I) By cover art

Fulfilling the promise of cell & gene therapies through manufacturing (Part I)

Listen for free

View show details

  • Summary

  • This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing.

    In this episode, Fierce Pharma’s Fraiser Kansteiner sits down with Ori Biotech CEO Jason Foster and the Cell Therapy Manufacturing Center's CEO, Jason Bock. They delve into the current state of cell and gene therapy manufacturing and consider if the existing production methods can keep up with the potential of personalized medicines.

    They also dive into past hurdles in the space and highlight the varied approaches—including their own—that a new generation of cell and gene therapy manufacturing companies have been pioneering.

    To learn more about the topics in this episode:

    • Ori Biotech taps MD Anderson, National Resilience joint venture to put its automated cell and gene therapy manufacturing tech to the test

    See omnystudio.com/listener for privacy information.
    Show more Show less
Business & Careers Politics & Government
Show more Show less

What listeners say about Fulfilling the promise of cell & gene therapies through manufacturing (Part I)

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available